A randomized phase II clinical trial (NCT02362048) reported that the combination of BTK inhibitor acalabrutinib and pembrolizumab led to reduction of reductions in granulocytic (CD15+) MDSCs in peripheral blood of patient with pancreatic cancer, but the overall response rate and disease control rate were disappointing (132). This evidence concerns the gene BTK and familial pancreatic carcinoma.